B+
Bull case
20%
Probability
Target price
$5.50
+89.0% vs current
NKTX
NkartaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.75
-5.5% vs current
B-
Bear case
35%
Probability
Target price
$1.15
-60.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-19
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+42.8
Score
AI commentary
Primary-source support is solid for the quarter update, but external confirmation remains thin: there are no recent trusted-news items, no usable social aggregate, no analyst revision trail in the packet, and no clean public allogeneic CAR-NK autoimmune peer set. The 8-K and 10-Q improve visibility on cash runway and trial execution, yet the main evidence gap is still clinical efficacy. Because peer evidence is only loose event-volatility context, this remains a tentative monitoring name rather than a conviction bullish thesis.
RankAlpha Sentiment Codex - 2026-05-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystQ1 2026 filing keeps runway intact but does not close the efficacy gapMedium impact
The May 12 update says Nkarta had $266.7 million in cash, cash equivalents, restricted cash, and investments at March 31, 2026, expects current cash to fund operations into 2029, and reported a $27.8 million Q1 net loss on $25.0 million of R&D spend. That improves balance-sheet visibility, but it is still a pre-data update rather than clinical proof.[#8-K-2026-05-12] [#10-Q-2026-05-12]
2026-09-30catalystProtocol amendments may broaden access if enrollment execution improvesHigh impact
The May 12 update says IRB approval for protocol amendments has been secured across multiple sites for outpatient dosing, re-dosing, ending overnight monitoring, and adding a rheumatoid arthritis cohort to Ntrust-2. That can help enrollment and site access, but the benefit is contingent on execution and does not substitute for efficacy data.[#8-K-2026-05-12]
2026-12-31eventFirst Ntrust-1 / Ntrust-2 clinical data remain the main 2026 readoutHigh impact
Nkarta said initial clinical data from Ntrust-1 and Ntrust-2 are expected to be presented at a medical meeting in 2026, with patients now being dosed at 4 billion cells per dose x 3 doses across indications. This is still the central binary catalyst because the stock has no efficacy readout yet.[#8-K-2026-05-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-19 • Updated nightlySource: Internal modelMethodology